Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290465986> ?p ?o ?g. }
- W4290465986 abstract "We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease progression and clinical recovery time in patients with mild-to-moderate coronavirus disease 2019 (COVID-19), primarily Alpha variant.This was phase 3 of a phase 2/3 parallel-group, double-blind, randomized clinical trial. Outpatients with mild-to-moderate COVID-19 were randomized to single-dose regdanvimab 40 mg/kg (n = 656) or placebo (n = 659), alongside standard of care. The primary endpoint was COVID-19 disease progression up to day 28 among high-risk patients. Key secondary endpoints were disease progression (all randomized patients) and time to recovery (high-risk and all randomized patients).Of 1315 randomized patients, 880 were high risk; the majority were infected with Alpha variant. The proportion with disease progression was lower (14/446, 3.1% [95% confidence interval {CI}, 1.9%-5.2%] vs 48/434, 11.1% [95% CI, 8.4%-14.4%]; P < .001) and time to recovery was shorter (median, 9.27 days [95% CI, 8.27-11.05 days] vs not reached [95% CI, 12.35-not calculable]; P < .001) with regdanvimab than placebo. Consistent improvements were seen in all randomized and non-high-risk patients who received regdanvimab. Viral load reductions were more rapid with regdanvimab. Infusion-related reactions occurred in 11 patients (4/652 [0.6%] regdanvimab, 7/650 [1.1%] placebo). Treatment-emergent serious adverse events were reported in 5 of (4/652 [0.6%] regdanvimab and 1/650 [0.2%] placebo).Regdanvimab was an effective treatment for patients with mild-to-moderate COVID-19, significantly reducing disease progression and clinical recovery time without notable safety concerns prior to the emergence of the Omicron variant.NCT04602000; 2020-003369-20 (EudraCT)." @default.
- W4290465986 created "2022-08-08" @default.
- W4290465986 creator A5003229637 @default.
- W4290465986 creator A5008441151 @default.
- W4290465986 creator A5009707371 @default.
- W4290465986 creator A5025016732 @default.
- W4290465986 creator A5025306323 @default.
- W4290465986 creator A5030279733 @default.
- W4290465986 creator A5030279800 @default.
- W4290465986 creator A5035117544 @default.
- W4290465986 creator A5039192387 @default.
- W4290465986 creator A5043754356 @default.
- W4290465986 creator A5045375634 @default.
- W4290465986 creator A5045684901 @default.
- W4290465986 creator A5046625776 @default.
- W4290465986 creator A5049416849 @default.
- W4290465986 creator A5050681290 @default.
- W4290465986 creator A5055659413 @default.
- W4290465986 creator A5062224388 @default.
- W4290465986 creator A5064675224 @default.
- W4290465986 creator A5066408904 @default.
- W4290465986 creator A5067008785 @default.
- W4290465986 creator A5074243484 @default.
- W4290465986 creator A5082933795 @default.
- W4290465986 creator A5088539793 @default.
- W4290465986 creator A5091107907 @default.
- W4290465986 date "2022-08-01" @default.
- W4290465986 modified "2023-10-18" @default.
- W4290465986 title "A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019" @default.
- W4290465986 cites W2790991426 @default.
- W4290465986 cites W3037173725 @default.
- W4290465986 cites W3044464354 @default.
- W4290465986 cites W3080207836 @default.
- W4290465986 cites W3081838637 @default.
- W4290465986 cites W3091759688 @default.
- W4290465986 cites W3092891588 @default.
- W4290465986 cites W3096658347 @default.
- W4290465986 cites W3111431752 @default.
- W4290465986 cites W3119640713 @default.
- W4290465986 cites W3119881634 @default.
- W4290465986 cites W3121093151 @default.
- W4290465986 cites W3125712166 @default.
- W4290465986 cites W3155123963 @default.
- W4290465986 cites W3167429034 @default.
- W4290465986 cites W3175809015 @default.
- W4290465986 cites W3195688501 @default.
- W4290465986 cites W3200766981 @default.
- W4290465986 cites W3215399721 @default.
- W4290465986 cites W4206610449 @default.
- W4290465986 cites W4210311296 @default.
- W4290465986 cites W4212988737 @default.
- W4290465986 cites W4221072241 @default.
- W4290465986 cites W4221125725 @default.
- W4290465986 cites W4224287290 @default.
- W4290465986 cites W4226148899 @default.
- W4290465986 cites W4226164012 @default.
- W4290465986 cites W4226192094 @default.
- W4290465986 cites W4280630418 @default.
- W4290465986 cites W4285592184 @default.
- W4290465986 doi "https://doi.org/10.1093/ofid/ofac406" @default.
- W4290465986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36043180" @default.
- W4290465986 hasPublicationYear "2022" @default.
- W4290465986 type Work @default.
- W4290465986 citedByCount "11" @default.
- W4290465986 countsByYear W42904659862022 @default.
- W4290465986 countsByYear W42904659862023 @default.
- W4290465986 crossrefType "journal-article" @default.
- W4290465986 hasAuthorship W4290465986A5003229637 @default.
- W4290465986 hasAuthorship W4290465986A5008441151 @default.
- W4290465986 hasAuthorship W4290465986A5009707371 @default.
- W4290465986 hasAuthorship W4290465986A5025016732 @default.
- W4290465986 hasAuthorship W4290465986A5025306323 @default.
- W4290465986 hasAuthorship W4290465986A5030279733 @default.
- W4290465986 hasAuthorship W4290465986A5030279800 @default.
- W4290465986 hasAuthorship W4290465986A5035117544 @default.
- W4290465986 hasAuthorship W4290465986A5039192387 @default.
- W4290465986 hasAuthorship W4290465986A5043754356 @default.
- W4290465986 hasAuthorship W4290465986A5045375634 @default.
- W4290465986 hasAuthorship W4290465986A5045684901 @default.
- W4290465986 hasAuthorship W4290465986A5046625776 @default.
- W4290465986 hasAuthorship W4290465986A5049416849 @default.
- W4290465986 hasAuthorship W4290465986A5050681290 @default.
- W4290465986 hasAuthorship W4290465986A5055659413 @default.
- W4290465986 hasAuthorship W4290465986A5062224388 @default.
- W4290465986 hasAuthorship W4290465986A5064675224 @default.
- W4290465986 hasAuthorship W4290465986A5066408904 @default.
- W4290465986 hasAuthorship W4290465986A5067008785 @default.
- W4290465986 hasAuthorship W4290465986A5074243484 @default.
- W4290465986 hasAuthorship W4290465986A5082933795 @default.
- W4290465986 hasAuthorship W4290465986A5088539793 @default.
- W4290465986 hasAuthorship W4290465986A5091107907 @default.
- W4290465986 hasBestOaLocation W42904659861 @default.
- W4290465986 hasConcept C126322002 @default.
- W4290465986 hasConcept C141071460 @default.
- W4290465986 hasConcept C142724271 @default.
- W4290465986 hasConcept C168563851 @default.
- W4290465986 hasConcept C197934379 @default.
- W4290465986 hasConcept C203092338 @default.
- W4290465986 hasConcept C204787440 @default.
- W4290465986 hasConcept C27081682 @default.